QIAGEN N.V. (QGEN)

NL0015001WM6 - Common Stock

42.99  +0.24 (+0.56%)

After market: 42.99 0 (0%)

News Image
4 days ago - QIAGEN N.V.

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care //...

News Image
4 days ago - QIAGEN N.V.

Bessere Zusammenarbeit im Gesundheitswesen: QIAGEN stellt QIAstat-Dx Analyzer 2.0 mit Fernzugriff auf Testergebnisse vor

QIAstat-Dx Analyzer 2.0 mit Software-Version 1.6 ermöglicht mobilen Zugriff auf Testergebnisse, optimiert diagnostische Prozesse und verbessert die...

News Image
11 days ago - QIAGEN N.V.

QIAGEN und International Panel Physicians Association fördern gemeinsam Bewusstsein für Tuberkulose-Screenings

Gemeinsame Bildungsinitiative konzentriert sich auf die Vorteile des Interferon-Gamma-Release-Assays (IGRA) für medizinisches Fachpersonal // Aktualisierte...

News Image
11 days ago - QIAGEN N.V.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate...

News Image
18 days ago - QIAGEN N.V.

QIAGEN announces Form 20-F annual report filing for 2023 results

Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its...

News Image
a month ago - QIAGEN N.V.

QIAGEN ondersteunt de non-profit organisatie ZIZ met het NeuMoDx-testsysteem om de toegang tot snelle en betaalbare SOA-detectie en -behandeling te verbeteren

Door de NeuMoDx-technologie van QIAGEN kan ZIZ de openingsuren uitbreiden, thuisafname services toevoegen, kosten voor gezondheidszorg besparen en...

News Image
a month ago - QIAGEN N.V.

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven...

News Image
a month ago - QIAGEN N.V.

QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard...

News Image
a month ago - QIAGEN N.V.

Neue KI-gestützte biomedizinische Wissensdatenbank: QIAGEN beschleunigt datenbasierte Arzneimittelforschung

QIAGEN Biomedical KB-AI enthält mehr als 640 Millionen biomedizinische Beziehungen, darunter Kausalzusammenhänge zwischen Genen, Krankheiten und...

News Image
a month ago - Seeking Alpha

Qiagen stock upgraded at Morgan Stanley on valuation

Morgan Stanley upgrades Qiagen (QGEN) to Overweight from Equal-Weight noting that the valuation gap between the Dutch company and its peers could narrow. Read more here.

News Image
a month ago - QIAGEN N.V.

QIAGEN erhält ACT-Label für neue, umweltfreundlichere QIAwave‑Produkte und erste Platin-Zertifizierung von My Green Lab

Zusätzliche umweltfreundliche QIAwave-Kits für DNA- und RNA-Extraktion erhalten ACT‑Label dank deutlich besserem Umweltfaktor im Vergleich zu Standard-Kits // F&E-Labor für Probentechnologien von QIAGEN in Deutschland erhält Platin-Zertifizierung von My Green Lab; Pläne für weitere Zertifizierungen am Standort festgelegt // Kunststoffverpackungen und Treibhausgasemissionen sollen im Rahmen einer umfassenden ESG-Strategie weiter verringert werden

News Image
a month ago - QIAGEN N.V.

QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard...

News Image
2 months ago - Seeking Alpha

Qiagen Non-GAAP EPS of $0.55 in-line, revenue of $503M misses by $2.09M (NYSE:QGEN)

Qiagen's Q4 earnings report shows in-line Non-GAAP EPS of $0.55, but misses revenue expectations by $2.09M with $503M generated (+1.0% Y/Y).

News Image
2 months ago - QIAGEN N.V.

QIAGEN übertrifft Prognose für viertes Quartal 2023 aufgrund von Umsatzwachstum von 8% (CER) bei Nicht COVID-Produkten und Verbesserung der operativen Rentabilität

Q4 2023: Konzernumsatz von $509 Mio. (+2% bei tatsächlichen Kursen; +1% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,42;...

News Image
2 months ago - Seeking Alpha

Qiagen stock gains amid report potential buyer lining up advisors, financing

Qiagen (QGEN) stock rises 3.5% as potential buyer for the molecular testing firm reportedly lines up advisory and financing firms.

News Image
2 months ago - Seeking Alpha

Notable earnings after Tuesday's close

Major earnings expected after the bell on Tuesday include:Ford Motor Company (F)Gilead Sciences (GILD)Amgen (AMGN)Enphase Energy (ENPH) Snap (SNAP)Other...

News Image
2 months ago - QIAGEN N.V.

QIAGEN announces partnership with Penn State University to advance microbiome sciences

Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide...

News Image
2 months ago - QIAGEN N.V.

Neue Partnerschaft zwischen QIAGEN und Penn State University treibt Mikrobiomwissenschaften voran

Partnerschaft gestaltet Forschung, Bildung und Informationsarbeit auf dem Fachgebiet der Mikrobiome – der Gemeinschaft von Mikroorganismen in einer...

News Image
2 months ago - Seeking Alpha

Qiagen announces details of synthetic share repurchase plan of up to $300M (NYSE:QGEN)

Qiagen announces details for completion of synthetic share repurchase plan, including a reverse stock split and capital repayment to shareholders.

News Image
2 months ago - QIAGEN N.V.

QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $300 Mio. bekannt

VENLO, Niederlande, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Einzelheiten zum Abschluss seines...

News Image
2 months ago - QIAGEN N.V.

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion...

News Image
2 months ago - Seeking Alpha

Qiagen stock quickly ticks higher amid takeover speculaiton (NYSE:QGEN)

Qiagen (QGEN) stock rises 1% as renewed takeover talks circulate.

News Image
2 months ago - Seeking Alpha

Qiagen stock quickly ticks higher amid takeover speculation

Qiagen (QGEN) stock rises 1% as renewed takeover talks circulate.

News Image
3 months ago - QIAGEN N.V.

QIAGEN N.V. to release results for Q4 2023 and hold webcast

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for...

News Image
3 months ago - Seeking Alpha

QIAGEN announces plans to return approximately $300 million to shareholders (NYSE:QGEN)

QIAGEN N.V. announces a plan to return $300 million to shareholders through a synthetic share repurchase combining capital repayment and stock split.

News Image
3 months ago - QIAGEN N.V.

QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems

NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. ...

News Image
3 months ago - QIAGEN N.V.

QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt

Kapitalrückzahlung durch synthetischen Aktienrückkauf // Rückzahlung von bis zu $300 Mio. – von Aktionärinnen und Aktionären im Jahr 2023 genehmigter...

News Image
3 months ago - QIAGEN N.V.

QIAGEN announces plans to return approximately $300 million to shareholders

Capital return to be conducted through synthetic share repurchase // Return of up to $300 million – maximum approved by shareholders in 2023 – designed to...

News Image
3 months ago - QIAGEN N.V.

QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business

Investments into QDI to strengthen No. 1 industry position through profitable expansion into new geographic regions, market segments and enhanced product...

News Image
3 months ago - QIAGEN N.V.

QIAGEN verstärkt Investitionen in sein Bioinformatik-Geschäft QIAGEN Digital Insights

Investitionen in QIAGEN Digital Insights (QDI) stärken führende Branchenposition durch profitable Expansion in neue Regionen, Marktsegmente und erweiterte...

News Image
3 months ago - Seeking Alpha

QIAGEN expands business in Middle East with new regional headquarters (NYSE:QGEN)

QIAGEN expands business in the Middle East with new regional headquarters in Riyadh and public health initiatives in Saudi Arabia and Oman.

News Image
3 months ago - QIAGEN N.V.

QIAGEN expands business in Middle East with new regional headquarters and major projects

QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region // QIAGEN signed...

News Image
3 months ago - QIAGEN N.V.

QIAGEN expandiert im Nahen Osten mit neuer regionaler Zentrale und Großprojekten

QIAGEN eröffnet Anfang 2024 neue regionale Zentrale in Riad, Saudi-Arabien, um wachsende Präsenz vor Ort zu unterstützen // Absichtserklärung mit dem...